Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

por Garrett, Joan T., Chakrabarty, Anindita, Arteaga, Carlos L.
Publicado 2011

Genomic alterations of ERBB receptors in cancer: clinical implications

por Mishra, Rosalin, Hanker, Ariella B., Garrett, Joan T.
Publicado 2017

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

por Garrett, Joan T., Chakrabarty, Anindita, Arteaga, Carlos L.
Publicado 2018

HER3 signaling and targeted therapy in cancer

por Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Yuan, Long, Garrett, Joan T.
Publicado 2018

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

por Miller, Todd W, Rexer, Brent N, Garrett, Joan T, Arteaga, Carlos L
Publicado 2011

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

por Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Publicado 2021

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

por Patel, Hima, Mishra, Rosalin, Yacoub, Nour, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Publicado 2021

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

por Patel, Hima, Mishra, Rosalin, Wier, Adam, Mokhtarpour, Nazanin, Merino, Edward J., Garrett, Joan T.
Publicado 2023

Current Advances in the Treatment of BRAF-Mutant Melanoma

por Patel, Hima, Yacoub, Nour, Mishra, Rosalin, White, Aaron, Yuan, Long, Alanazi, Samar, Garrett, Joan T.
Publicado 2020

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels

por Yuan, Long, Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Wei, Xin, Ma, Zhijun, Garrett, Joan T.
Publicado 2020

Activating HER3 mutations in breast cancer

por Mishra, Rosalin, Alanazi, Samar, Yuan, Long, Solomon, Thomas, Thaker, Tarjani M., Jura, Natalia, Garrett, Joan T.
Publicado 2018

HER3 Alterations in Cancer and Potential Clinical Implications

por Kilroy, Mary Kate, Park, SoYoung, Feroz, Wasim, Patel, Hima, Mishra, Rosalin, Alanazi, Samar, Garrett, Joan T.
Publicado 2022

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

por Alanazi, Samar M., Feroz, Wasim, Mishra, Rosalin, Kilroy, Mary Kate, Patel, Hima, Yuan, Long, Storr, Sarah J., Garrett, Joan T.
Publicado 2023

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma

por Yuan, Long, Mishra, Rosalin, Patel, Hima, Abdulsalam, Safnas, Greis, Kenneth D., Kadekaro, Ana Luisa, Merino, Edward J., Garrett, Joan T.
Publicado 2018

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces...

por Mishra, Rosalin, Yuan, Long, Patel, Hima, Karve, Aniruddha S., Zhu, Haizhou, White, Aaron, Alanazi, Samar, Desai, Pankaj, Merino, Edward J., Garrett, Joan T.
Publicado 2021